Antibody-based therapy in Alzheimer's disease

Bibliography

• Alzheimer's Disease International. World Alzheimer Report. Alzheimer's Disease International, London; 2009
   Google Scholar
• Mandelkow E, von Bergen M, Biernat J, Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol 2007;17:83-90
   PubMed Web of Science ®Google Scholar
• Rajendran L, Honsho M, Zahn TR, Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci USA 2006;103:11172-7
   PubMed Web of Science ®Google Scholar
• Kaether C, Schmitt S, Willem M, Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface. Traffic 2006;7:408-15
   PubMed Web of Science ®Google Scholar
• Cleary JP, Walsh DM, Hofmeister JJ, Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005;8:79-84
   PubMed Web of Science ®Google Scholar
• Klyubin I, Walsh DM, Lemere CA, Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005;11:556-61
   PubMed Web of Science ®Google Scholar
• Townsend M, Shankar GM, Mehta T, Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006;572:477-92
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004;6:1054-61
   PubMed Web of Science ®Google Scholar
• Khandogin J, Brooks CL III. Linking folding with aggregation in Alzheimer's beta-amyloid peptides. Proc Natl Acad Sci USA 2007;104:16880-5
   PubMed Web of Science ®Google Scholar
• Mangialasche F, Solomon A, Winblad B, Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9:702-16
   PubMed Web of Science ®Google Scholar
• Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 2008;31:175-93
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE, Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-5
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-5
   PubMed Web of Science ®Google Scholar
• Solomon B, Koppel R, Frankel D, Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997;94:4109-12
   PubMed Web of Science ®Google Scholar
• Solomon B, Koppel R, Hanan E, Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA 1996;93:452-5
   PubMed Web of Science ®Google Scholar
• Janus C, Pearson J, McLaurin J, Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-82
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Scholtzova H, Mehta PD, Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001;159:439-47
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Knudsen E, Asuni A, An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 2004;24:6277-82
   PubMed Web of Science ®Google Scholar
• Asuni AA, Boutajangout A, Scholtzova H, Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci 2006;24:2530-42
   PubMed Web of Science ®Google Scholar
• Kotilinek LA, Bacskai B, Westerman M, Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002;22:6331-5
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-9
   PubMed Web of Science ®Google Scholar
• Bard F, Barbour R, Cannon C, Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003;100:2023-8
   PubMed Web of Science ®Google Scholar
• Dodart JC, Bales KR, Gannon KS, Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-7
   PubMed Web of Science ®Google Scholar
• Lee EB, Leng LZ, Zhang B, Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006;281:4292-9
   PubMed Web of Science ®Google Scholar
• McLaurin J, Cecal R, Kierstead ME, Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002;8:1263-9
   PubMed Web of Science ®Google Scholar
• Xu S, Gaskin F. Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech Ageing Dev 1997;94:213-22
   PubMed Web of Science ®Google Scholar
• Geylis V, Kourilov V, Meiner Z, Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 2005;26:597-606
   PubMed Web of Science ®Google Scholar
• Banks WA, Farr SA, Morley JE, Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment. Exp Neurol 2007;206:248-56
   PubMed Web of Science ®Google Scholar
• Oddo S, Billings L, Kesslak JP, Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321-32
   PubMed Web of Science ®Google Scholar
• Dodel R, Hampel H, Depboylu C, Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002;52:253-6
   PubMed Web of Science ®Google Scholar
• Du Y, Wei X, Dodel R, Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003;126:1935-9
   PubMed Web of Science ®Google Scholar
• Bayer AJ, Bullock R, Jones RW, Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005;64:94-101
   PubMed Web of Science ®Google Scholar
• Hock C, Konietzko U, Streffer JR, Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-54
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54
   PubMed Web of Science ®Google Scholar
• Ferrer I, Boada RM, Sanchez Guerra ML, Neuropathology and pathogenesis of encephalitis following amyloid beta immunization in Alzheimer's disease. Brain Pathol 2004;14:11-20
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-52
   PubMed Web of Science ®Google Scholar
• Masliah E, Hansen L, Adame A, Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005;64:129-31
   PubMed Web of Science ®Google Scholar
• Furlan R, Brambilla E, Sanvito F, Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 2003;126:285-91
   PubMed Web of Science ®Google Scholar
• Holmes C, Boche D, Wilkinson D, Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-23
   PubMed Web of Science ®Google Scholar
• Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002;3:824-8
   PubMed Web of Science ®Google Scholar
• Weksler ME. The immunotherapy of Alzheimer's disease. Immun Ageing 2004;1:2
   PubMedGoogle Scholar
• Dodel R, Neff F, Noelker C, Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 2010;70:513-28
   PubMed Web of Science ®Google Scholar
• Mamikonyan G, Necula M, Mkrtichyan M, Anti-A beta1–11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem 2007;282:22376-86
   PubMed Web of Science ®Google Scholar
• Bacskai BJ, Kajdasz ST, McLellan ME, Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002;22:7873-8
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Yokoseki T, Shibata M, Suppression of Abeta deposition in brain by peripheral administration of Fab fragments of anti-seed antibody. Biochem Biophys Res Commun 2005;335:45-7
   PubMed Web of Science ®Google Scholar
• Tamura Y, Hamajima K, Matsui K, The F(ab)′2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiol Dis 2005;20:541-9
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002;295:2264-7
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Saito M, LaFrancois J, Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003;23:29-33
   PubMed Web of Science ®Google Scholar
• Sagare A, Deane R, Bell RD, Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007;13:1029-31
   PubMed Web of Science ®Google Scholar
• Seubert P, Barbour R, Khan K, Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 2008;5:65-71
   PubMed Web of Science ®Google Scholar
• Levites Y, Smithson LA, Price RW, Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J 2006;20:2576-8
   PubMed Web of Science ®Google Scholar
• Yamada K, Yabuki C, Seubert P, Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 2009;29:11393-8
   PubMed Web of Science ®Google Scholar
• Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006;443:768-73
   PubMed Web of Science ®Google Scholar
• Knobloch M, Farinelli M, Konietzko U, Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci 2007;29:7648-53
   Google Scholar
• Dahlgren KN, Manelli AM, Stine WB Jr, Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002;277:32046-53
   PubMed Web of Science ®Google Scholar
• Liu R, Yuan B, Emadi S, Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent Abeta-induced neurotoxicity. Biochemistry 2004;43:6959-67
   PubMed Web of Science ®Google Scholar
• Mohajeri MH, Saini K, Schultz JG, Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 2002;277:33012-7
   PubMed Web of Science ®Google Scholar
• Gaugler MN, Tracy J, Kuhnle K, Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo. FEBS Lett 2005;579:753-6
   PubMed Web of Science ®Google Scholar
• Gray AJ, Sakaguchi G, Shiratori C, Antibody against C-terminal Abeta selectively elevates plasma Abeta. Neuroreport 2007;18:293-6
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Rojiani A, Rosenthal A, Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004;1:24
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Rojiani A, Rosenthal A, Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004;24:6144-51
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Alamed J, Gottschall PE, Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 2006;26:5340-6
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Boncristiano S, Bondolfi L, Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002;298:1379
   PubMed Web of Science ®Google Scholar
• Racke MM, Boone LI, Hepburn DL, Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005;25:629-36
   PubMed Web of Science ®Google Scholar
• Moretto N, Bolchi A, Rivetti C, Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem 2007;382:11436-45
   Google Scholar
• Manea M, Mezo G, Hudecz F, Polypeptide conjugates comprising a beta-amyloid plaque-specific epitope as new vaccine structures against Alzheimer's disease. Biopolymers 2004;76:503-11
   PubMed Web of Science ®Google Scholar
• Manea M, Hudecz F, Przybylski M, Synthesis, solution conformation, and antibody recognition of oligotuftsin-based conjugates containing a beta-amyloid(4-10) plaque-specific epitope. Bioconjug Chem 2005;16:921-8
   PubMed Web of Science ®Google Scholar
• Meli G, Visintin M, Cannistraci I, Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. J Mol Biol 2009;387:584-606
   PubMed Web of Science ®Google Scholar
• Mc Donald JM, Savva GM, Brayne C, The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010;133:1328-41
   PubMed Web of Science ®Google Scholar
• Tomic JL, Pensalfini A, Head E, Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009;35:352-8
   PubMed Web of Science ®Google Scholar
• Kayed R, Head E, Thompson JL, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-9
   PubMed Web of Science ®Google Scholar
• Lambert MP, Viola KL, Chromy BA, Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 2001;79:595-605
   PubMed Web of Science ®Google Scholar
• Lambert MP, Velasco PT, Chang L, Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 2007;100:23-35
   PubMed Web of Science ®Google Scholar
• Shankar GM, Bloodgood BL, Townsend M, Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007;27:2866-75
   PubMed Web of Science ®Google Scholar
• Vasilevko V, Pop V, Kim HJ, Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis 2010;39:301-10
   PubMed Web of Science ®Google Scholar
• Lindhagen-Persson M, Brannstrom K, Vestling M, Amyloid-beta oligomer specificity mediated by the IgM isotype – implications for a specific protective mechanism exerted by endogenous auto-antibodies. PLoS One 2010;5:e13928
   PubMedGoogle Scholar
• Goni F, Prelli F, Ji Y, Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One 2010;5:e13391
   PubMed Web of Science ®Google Scholar
• Balducci C, Beeg M, Stravalaci M, Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA 2010;107:2295-300
   PubMed Web of Science ®Google Scholar
• Lauren J, Gimbel DA, Nygaard HB, Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009;457:1128-32
   PubMed Web of Science ®Google Scholar
• Gimbel DA, Nygaard HB, Coffey EE, Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci 2010;30:6367-74
   PubMed Web of Science ®Google Scholar
• Chung E, Ji Y, Sun Y, Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci 2010;11:130
   PubMed Web of Science ®Google Scholar
• Nelson AL. Antibody fragments: hope and hype. MAbs 2010;2:77-83
   PubMed Web of Science ®Google Scholar
• Frenkel D, Solomon B, Benhar I. Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody. J Neuroimmunol 2000;106:23-31
   PubMed Web of Science ®Google Scholar
• Solorzano-Vargas RS, Vasilevko V, Acero G, Epitope mapping and neuroprotective properties of a human single chain FV antibody that binds an internal epitope of amyloid-beta 1-42. Mol Immunol 2008;45:881-6
   PubMed Web of Science ®Google Scholar
• Yue S, Li Y, Wang X, The toxicity of beta-amyloid is attenuated by interaction with its specific human scFv E3 in vitro. Life Sci 2008;82:1249-55
   PubMed Web of Science ®Google Scholar
• Fukuchi K, Accavitti-Loper MA, Kim HD, Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model. Biochem Biophys Res Commun 2006;344:79-86
   PubMed Web of Science ®Google Scholar
• Boado RJ, Lu JZ, Hui EK, IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol Bioeng 2010;105:627-35
   PubMed Web of Science ®Google Scholar
• Hayashi I, Takatori S, Urano Y, Single chain variable fragment against nicastrin inhibits the gamma-secretase activity. J Biol Chem 2009;284:27838-47
   PubMed Web of Science ®Google Scholar
• Paganetti P, Calanca V, Galli C, beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J Cell Biol 2005;168:863-8
   PubMed Web of Science ®Google Scholar
• Fukuchi K, Tahara K, Kim HD, Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis 2006;23:502-11
   PubMed Web of Science ®Google Scholar
• Sudol KL, Mastrangelo MA, Narrow WC, Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease. Mol Ther 2009;17:2031-40
   PubMed Web of Science ®Google Scholar
• Habicht G, Haupt C, Friedrich RP, Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci USA 2007;104:19232-7
   PubMed Web of Science ®Google Scholar
• Robert R, Dolezal O, Waddington L, Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng Des Sel 2009;22:199-208
   PubMed Web of Science ®Google Scholar
• Rangan SK, Liu R, Brune D, Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry 2003;42:14328-34
   PubMed Web of Science ®Google Scholar
• Paul S, Volle DJ, Beach CM, Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 1989;244:1158-62
   PubMed Web of Science ®Google Scholar
• Taguchi H, Planque S, Nishiyama Y, Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 2008;283:4714-22
   PubMed Web of Science ®Google Scholar
• Kasturirangan S, Brune D, Sierks M. Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments. Biotechnol Prog 2009;25:1054-63
   PubMed Web of Science ®Google Scholar
• Deane R, Du YS, Submamaryan RK, RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907-13
   PubMed Web of Science ®Google Scholar
• Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004;43:605-8
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 2004;89:807-11
   PubMed Web of Science ®Google Scholar
• Deane R, Sagare A, Hamm K, IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 2005;25:11495-503
   PubMed Web of Science ®Google Scholar
• Du Y, Dodel R, Hampel H, Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001;57:801-5
   PubMed Web of Science ®Google Scholar
• Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res 2006;84:434-43
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res 2009;6:446-50
   PubMed Web of Science ®Google Scholar
• Ubhi K, Masliah E. Recent advances in the development of immunotherapies for tauopathies. Exp Neurol 2010: published online 21 October 2010, doi:10.1016/j.expneurol.2010.10.007
   Google Scholar
• Asuni AA, Boutajangout A, Quartermain D, Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007;27:9115-29
   PubMed Web of Science ®Google Scholar
• Kayed R, Jackson GR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol 2009;21:359-63
   PubMed Web of Science ®Google Scholar
• Weaver CL, Espinoza M, Kress Y, Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 2000;21:719-27
   PubMed Web of Science ®Google Scholar
• Boimel M, Grigoriadis N, Lourbopoulos A, Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010;224:472-85
   PubMed Web of Science ®Google Scholar
• Rosenmann H, Meiner Z, Geylis V, Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 2006;410:90-3
   PubMed Web of Science ®Google Scholar
• Black RS, Sperling RA, Safirstein B, A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:198-203
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Gilman S, A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70
   PubMed Web of Science ®Google Scholar
• Rinne JO, Brooks DJ, Rossor MN, 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72
   PubMed Web of Science ®Google Scholar
• Klunk WE, Engler H, Nordberg A, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19
   PubMed Web of Science ®Google Scholar
• Siemers ER, Friedrich S, Dean RA, Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33:67-73
   PubMed Web of Science ®Google Scholar
• Jicha GA. Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’? Expert Opin Biol Ther 2009;9:481-91
   PubMed Web of Science ®Google Scholar
• Multiple IV dose study of PF-04360365 in patients with mild to moderate Alzheimer's disease. Bethesda, MD: clinicaltrials.gov, 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00722046?term=NCT00722046&rank=1 [Last accessed 9 January 2010]
   Google Scholar
• A multiple ascending dose study of R1450 in patients with Alzheimer disease. Bethesda, MD: clinicaltrials.gov, 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00531804?term=NCT00531804&rank=1 [Last accessed 9 January 2010]
   Google Scholar
• A Study of V950 in people with alzheimer disease (V950-001). Bethesda, MD: clinicaltrials.gov, 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00464334?term=NCT00464334&rank=1 [Last accessed 9 January 2010]
   Google Scholar
• A study of the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of anti-Abeta (MABT5102A) in patients with Alzheimer's disease. Bethesda, MD: clinicaltrials.gov, 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00736775?term=NCT00736775&rank=1 [Last accessed 9 January 2010]
   Google Scholar
• A clinical study to assess single and repeat doses of a new medication (GSK933776) in patients with Alzheimer's disease. Bethesda, MD: clinicaltrials.gov, 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00459550?term=NCT00459550&rank=1 [Last accessed 9 January 2010]
   Google Scholar
• Stangel M, Pul R. Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol 2006;253(Suppl 5):V18-24
   PubMedGoogle Scholar
• Weksler ME, Relkin N, Turkenich R, Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002;37:943-8
   PubMed Web of Science ®Google Scholar
• Britschgi M, Olin CE, Johns HT, Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci USA 2009;106:12145-50
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Gershwin E, Meroni PL. Autoantibodies. 2nd edition. Elsevier Science & Technology, Amsterdam; 2007
   Google Scholar
• Dodel RC, Du Y, Depboylu C, Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1472-4
   PubMed Web of Science ®Google Scholar
• Relkin NR, Szabo P, Adamiak B, 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30:1728-36
   PubMed Web of Science ®Google Scholar
• Kountouris D. Therapeutic effects of piracetam combined with intravenous immunoglobulin premature of Alzheimer type. J Neural Transm 2000;5:18
   Google Scholar
• A phase 3 study evaluating safety and effectiveness of immune globulin intravenous (IGIV 10%) for the treatment of mild to moderate Alzheimer's disease. Bethesda, MD: clinicaltrials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00818662?term=NCT00818662&rank=1 [Last accessed 9 January 2010]
   Google Scholar
• Study of octagam 10% on the treatment of mild to moderate Alzheimer's patients. Bethesda, MD: clinicaltrials.gov, 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00812565?term=NCT00812565&rank=1 [Last accessed 9 January 2010]
   Google Scholar
• Shankle WR. Longitudinal measure of IVIG treatment effect in patients with Alzheimer's and Lewy Body disease. Abstract ICAD 2009;P3:43
   Google Scholar
• Fillit H, Hess G, Hill J, IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009;73:180-5
   PubMed Web of Science ®Google Scholar
• Maguire-Zeiss KA, Federoff HJ. Convergent pathobiologic model of Parkinson's disease. Ann NY Acad Sci 2003;991:152-66
   PubMed Web of Science ®Google Scholar
• Emadi S, Barkhordarian H, Wang MS, Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol 2007;368:1132-44
   PubMed Web of Science ®Google Scholar
• Benner EJ, Mosley RL, Destache CJ, Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2004;101:9435-40
   PubMed Web of Science ®Google Scholar
• Emadi S, Liu R, Yuan B, Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 2004;43:2871-8
   PubMed Web of Science ®Google Scholar
• Zhou C, Emadi S, Sierks MR, A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 2004;10:1023-31
   PubMed Web of Science ®Google Scholar
• Maguire-Zeiss KA, Wang CI, Yehling E, Identification of human alpha-synuclein specific single chain antibodies. Biochem Biophys Res Commun 2006;349:1198-205
   PubMed Web of Science ®Google Scholar
• Lynch SM, Zhou C, Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol 2008;377:136-47
   PubMed Web of Science ®Google Scholar
• Mougenot AL, Betemps D, Hogeveen KN, Production of a monoclonal antibody, against human alpha-synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the alpha-synuclein locus. J Neurosci Methods 2010;192:268-76
   PubMed Web of Science ®Google Scholar
• Aguzzi A, O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 2010;9:237-48
   PubMed Web of Science ®Google Scholar
• Peretz D, Williamson RA, Kaneko K, Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001;412:739-43
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Nakamura N, Aosasa M, Inhibition of prion propagation in scrapie-infected mouse neuroblastoma cell lines using mouse monoclonal antibodies against prion protein. Biochem Biophys Res Commun 2005;335:197-204
   PubMed Web of Science ®Google Scholar
• Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci USA 2001;98:9295-9
   PubMed Web of Science ®Google Scholar
• Gilch S, Wopfner F, Renner-Muller I, Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J Biol Chem 2003;278:18524-31
   PubMed Web of Science ®Google Scholar
• White AR, Enever P, Tayebi M, Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003;422:80-3
   PubMed Web of Science ®Google Scholar
• Pilon J, Loiacono C, Okeson D, Anti-prion activity generated by a novel vaccine formulation. Neurosci Lett 2007;429:161-4
   PubMed Web of Science ®Google Scholar
• Wuertzer CA, Sullivan MA, Qiu X, CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 2008;16:481-6
   PubMed Web of Science ®Google Scholar
• Song CH, Furuoka H, Kim CL, Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. J Gen Virol 2008;89:1533-44
   PubMed Web of Science ®Google Scholar
• Campana V, Zentilin L, Mirabile I, Development of antibody fragments for immunotherapy of prion diseases. Biochem J 2009;418:507-15
   PubMed Web of Science ®Google Scholar
• Tayebi M, Collinge J, Hawke S. Unswitched immunoglobulin M response prolongs mouse survival in prion disease. J Gen Virol 2009;90:777-82
   PubMed Web of Science ®Google Scholar
• Heppner FL, Musahl C, Arrighi I, Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001;294:178-82
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Brown DR, Daniels M, Immunization delays the onset of prion disease in mice. Am J Pathol 2002;161:13-17
   PubMed Web of Science ®Google Scholar
• Schwarz A, Kratke O, Burwinkel M, Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 2003;350:187-9
   PubMed Web of Science ®Google Scholar
• Goni F, Knudsen E, Schreiber F, Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 2005;133:413-21
   PubMed Web of Science ®Google Scholar
• Goni F, Prelli F, Schreiber F, High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience 2008;153:679-86
   PubMed Web of Science ®Google Scholar
• Donofrio G, Heppner FL, Polymenidou M, Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol 2005;79:8330-8
   PubMed Web of Science ®Google Scholar
• Tayebi M, David MA, Bate C, Epitope specific anti-prion antibodies upregulate apolipoprotein E and disrupt membrane cholesterol homeostasis. J Gen Virol 2010; 91:3105-15
   PubMed Web of Science ®Google Scholar
• Lecerf JM, Shirley TL, Zhu Q, Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 2001;98:4764-9
   PubMed Web of Science ®Google Scholar
• Miller TW, Zhou C, Gines S, A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiol Dis 2005;19:47-56
   PubMed Web of Science ®Google Scholar
• Murphy RC, Messer A. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Brain Res Mol Brain Res 2004;121:141-5
   PubMedGoogle Scholar
• Wolfgang WJ, Miller TW, Webster JM, Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci USA 2005;102:11563-8
   PubMed Web of Science ®Google Scholar
• Gros-Louis F, Soucy G, Lariviere R, Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010;113:1188-99
   PubMed Web of Science ®Google Scholar
• Meucci N, Nobile-Orazio E, Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol 1996;243:117-20
   PubMed Web of Science ®Google Scholar
• Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol 2003;2:215-20
   PubMed Web of Science ®Google Scholar
• Bell RD, Sagare AP, Friedman AE, Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007;27:909-18
   PubMed Web of Science ®Google Scholar
• Farrer LA, Cupples LA, Haines JL, Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-56
   PubMed Web of Science ®Google Scholar
• Boche D, Denham N, Holmes C, Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 2010;120:369-84
   PubMed Web of Science ®Google Scholar